Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Fineline Cube Feb 13, 2026
Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Fineline Cube Feb 13, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Deals

Suzhou Elite Analytical Instruments Secures Over $14 Million in Initial Funding Round

Fineline Cube Jan 5, 2024

Suzhou Elite Analytical Instruments Co., Ltd, a leading specialist in liquid chromatography based in China,...

Company Drug

Jiangsu Vcare PharmaTech Submits NDA to US FDA for Vicagrel, a P2Y12 Receptor Antagonist

Fineline Cube Jan 5, 2024

Jiangsu Vcare PharmaTech Co., Ltd, a Chinese pharmaceutical company, has submitted a New Drug Application...

Company Deals

Allorion Therapeutics and Avenzo Seal Deal for Global Rights to CDK2 Inhibitor

Fineline Cube Jan 5, 2024

China-based Allorion Therapeutics has entered into a licensing agreement with Avenzo Therapeutics Inc., granting the...

Company Drug

BMS’s Sotyktu, First TYK2 Inhibitor, Hits Chinese Market

Fineline Cube Jan 5, 2024

US pharmaceutical giant Bristol Myers Squibb (BMS, NYSE: BMY) has announced the market launch of...

Legal / IP

China’s National People’s Congress Approves Stricter Punishments for Sector-Specific Bribery

Fineline Cube Jan 4, 2024

The 7th meeting of the 14th National People’s Congress Standing Committee has passed the latest...

Company Deals Legal / IP

Daiichi Sankyo and Esperion Therapeutics Amend Collaboration on Antilipidemic Drugs

Fineline Cube Jan 4, 2024

Daiichi Sankyo (TYO: 4568)’s European subsidiary, a Japanese pharmaceutical company, has entered into a collaboration...

Company Drug

Shanghai BDgene Technology’s Thalassemia Gene Therapy BD211 Clears NMPA for Clinical Trials

Fineline Cube Jan 4, 2024

Shanghai BDgene Technology Co., Ltd, a specialist in gene therapy, has received clinical trial approval...

Company Drug

Belief BioMed Group Initiates Clinical Study for Hemophilia A Gene Therapy BBM-H803 in China

Fineline Cube Jan 4, 2024

Belief BioMed Group, a Shanghai-based gene therapy specialist, has announced the first subject dosing in...

Company Deals

IASO Biotherapeutics and Umoja Biopharma Join Forces for Innovative Cell and Gene Therapies Development

Fineline Cube Jan 4, 2024

IASO Biotherapeutics, a China-based company, and Umoja Biopharma, a California-headquartered developer of off-the-shelf cell therapies,...

Company Deals

Full-Life Technologies Secures USD 63.3 Million in Financing to Boost Radiotherapeutics Pipeline and Manufacturing

Fineline Cube Jan 4, 2024

Full-Life Technologies Ltd, a global radiotherapeutics company with a presence in Belgium, Germany, and China,...

Company Drug

Jiangsu Hengrui Pharmaceuticals Secures NMPA Approval for Abiraterone in Prostate Cancer Treatment

Fineline Cube Jan 4, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received marketing approval...

Company Drug

ImmunoTech Biopharm Commences Patient Enrollment in Phase II Study for CAR-T-19 Injection

Fineline Cube Jan 4, 2024

ImmunoTech Biopharm Ltd, a China-based specialist in chimeric antigen receptor T-cell (CAR-T) therapies (HKG: 6978),...

Company

Brii Biosciences Appoints Dr. Brian Alvin Johns as Chief Scientific Officer to Lead Pipeline Strategy

Fineline Cube Jan 4, 2024

Brii Biosciences Ltd (HKG: 2137), a leading biotechnology company based in China, has announced the...

Company Deals

GenScipt Subsidiary Legend Biotech Finalizes Licensing Deal with Novartis for DLL3 CAR-T Therapies

Fineline Cube Jan 4, 2024

GenScipt Biotech Corp., a China-based Contract Development and Manufacturing Organization (CDMO) (HKG: 1548), has announced...

Company Drug

Sino Biopharmaceutical Ltd Secures Exclusive Rights for Generic Everolimus in China

Fineline Cube Jan 4, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading pharmaceutical company based in China, has announced that...

Company Deals

Kexing Pharmaceutical Enters Global Licensing Agreement with Xiling Lab for Eribulin Generic

Fineline Cube Jan 4, 2024

China-based Kexing Pharmaceutical (SHA: 688136) has entered into a global licensing and supply agreement with...

Company Deals

Bio-Thera Solutions Grants Macter International Exclusive Rights to Avzivi in Pakistan and Afghanistan

Fineline Cube Jan 4, 2024

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement...

Company Deals

Boehringer Ingelheim Partners with Suzhou Ribo Life Science to Develop siRNA Therapies for NASH/MASH

Fineline Cube Jan 4, 2024

Boehringer Ingelheim (BI), a Germany-headquartered pharmaceutical company, has entered into a collaboration agreement with Suzhou...

Company Drug

Sciwind Biosciences’ Ecnolgutide Shows Promising Phase III Results in Type 2 Diabetes Treatment

Fineline Cube Jan 4, 2024

Sciwind Biosciences Co., Ltd, a China-based pharmaceutical company, has released the latest topline Phase III...

Company Deals

JW Therapeutics and 2seventy Bio Ink Exclusive Deal for CAR-T Cell Therapy in Greater China

Fineline Cube Jan 3, 2024

JW Therapeutics (HKG: 2126), a biopharmaceutical company based in China, has announced an exclusive collaboration...

Posts pagination

1 … 379 380 381 … 624

Recent updates

  • Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar
  • First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging
  • CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility
  • GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%
  • Novocure’s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Bio-Thera’s Gotenfia Wins European Approval as Simponi Biosimilar

Company Deals

First Imaging Raises $14.5 Million to Advance AI-Powered Intraoperative Imaging

Company

CARsgen Therapeutics to Invest $54 Million in Shanghai CAR-T Manufacturing Facility

Company

GSK Reports 7% Revenue Growth to $44.7 Billion in 2025; Oncology Surges 43%

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.